Clinical Trials in Dallas

Showing 13461-13480 of 17,468 trials

A Study of RG7667 in Healthy Volunteers

NCT01496755

This randomized, double-blind, placebo-controlled study will evaluate the safety and pharmacokinetics of RG7667 in healthy volunteers. Subjects will be randomized in cohorts to receive either single/multiple doses of RG7667 intravenously or placebo. Anticipated time on study treatment is up to 57 days with a 12-week follow-up.

Healthy Volunteer

Genentech, Inc.170 participantsStarted Jan 2012

Daytona Beach, Florida, United States • Honolulu, Hawaii, United States • Evansville, Indiana, United States +2 more locations

COMPLETEDPhase 2< 1 mile

A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease

NCT01609140

The purpose of this study is to evaluate the safety and cholesterol lowering effects of MPSK3169A when given as subcutaneous (SC) injections over a 24-week period to patients with a high risk of cardiovascular events and LDL-c levels well above goal.

Coronary Heart Disease

Genentech, Inc.248 participantsStarted May 2012

Goodyear, Arizona, United States • Carmichael, California, United States • Spring Valley, California, United States +70 more locations

A Study of RG7667 in Healthy Volunteers

A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease

Find Trials by Condition in Dallas

A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis

A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

A Study of R547 in Patients With Advanced Solid Tumors.

A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.

A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors

A Study of Mircera for the Treatment of Anemia in Dialysis Patients

A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.

SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease

A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck

A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis

A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)